texas oncology more breakthroughs. more victories

Share:

 
 

Jason M. Melear, M.D.

Jason M. Melear, M.D. Photo

Provider Type: Physician

Specialties:
Board Certifications:
  • Internal Medicine
  • Medical Oncology

Education

  • Fellowship in Oncology (1999-2001)
    Baylor University Medical Center, Dallas, TX
  • Resident, Internal Medicine (1996-1999)
    Baylor University Medical Center, Dallas, TX
  • Medical Doctorate (1992-1996)
    Texas Tech University School of Medicine
  • Bachelor of Arts in Biology (1987-1991)
    University of Texas, Austin, TX

Research Interest

He has a strong interest in research with special focus in hematologic malignancies and Phase I trials.

  • Principal investigator in Austin area Myeloma, Lymphoma, and Leukemia trials.
  • Principal Investigator multiple Austin area Phase I trials.

Medical Practice

  • Texas Oncology Board of Directors (2011 – 2014)
  • US Oncology Hematology Research Committee (2013 – present)
  • US Oncology Phase I Research Committee (2014 – present)
  • Austin Area Research Leader (2014 – present)
  • Area Director Austin (2015 – present)

Other Information

Dr. Melear was born in Louisville, Kentucky and moved to Houston, Texas while in high school. He is married and has three children. He enjoys spending time with his family and traveling.

Publications

  • Daratumumab, Bortezomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed and Relapsed Multiple Myeloma: LYRA Study

    British Journal of Haematology, 2019

  • Phase IIIB Randomized Study of Lenalidomide and Rituximab Followed by Maintenance in Relapsed/Refractory Non Hodgkins Lymphoma in Patients With Double Refractory or Early Relapsed Follicular Lymphoma

    Journal of Clinical Oncology, 2017

  • BBI608-503-103HCC: A Phase Ib/II Clinical Study of Napabucasin (BBI608) in Combination With Sorafenib or Amcasertib (BBI503) in Combination With Sorafenib (Sor) in Adult Patients With Hepatocellular Carcinoma (HCC)

    Journal of Clinical Oncology, 2017

  • MAGNIFY: Phase IIIB Randomized Study of Lenalidomide and Rituximab Followed by Lenalidomide Versus Rituximab Maintenance in Subjects With Relapsed/Refractory Follicular, Marginal Zone, and Mantle Cell Lymphoma

    American Society of Hematology, 2016

  • Ublituximab in Combination With Ibrutinib Is Highly Active in Patients With Relapsed and/or Refractory Mantle Cell Lymphoma. Results of a Phase II Trial

    Blood, 2015